Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Edmonton
Clinical trial register · Canada

Clinical Trials in Edmonton, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Canada and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6553 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:20 UTC
6553
Studies in scope
all four open statuses
3487
Recruiting now
open to new participants
880
Lead sponsors
across recruiting studies
Top sites
Toronto 2818 Montreal 1913 Vancouver 1187 Calgary 1068 Edmonton 1018
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University of Alberta175 AstraZeneca52 AbbVie36 National Cancer Institute (NCI)27 Merck Sharp & Dohme LLC26 Janssen Research & Development, LLC22 Canadian Cancer Trials Group21 AHS Cancer Control Alberta21 Pfizer21 Novartis Pharmaceuticals20 Children's Oncology Group19 University of Calgary19 Bristol-Myers Squibb16 Sanofi15 Eli Lilly and Company14 Hoffmann-La Roche14 Incyte Corporation11 Novo Nordisk A/S10 University of British Columbia9 University Health Network, Toronto9 Population Health Research Institute8 GlaxoSmithKline8 Regeneron Pharmaceuticals8 Amgen8 Alexion Pharmaceuticals, Inc.7 Boehringer Ingelheim7 Celgene6 Sunnybrook Health Sciences Centre6 Bayer6 NRG Oncology6 Seagen, a wholly owned subsidiary of Pfizer5 Ottawa Hospital Research Institute5 BeOne Medicines5 Takeda5 Radiation Therapy Oncology Group4 McGill University Health Centre/Research Institute of the McGill University Health Centre4 ModernaTX, Inc.4 Celldex Therapeutics4 The Hospital for Sick Children4 Mirum Pharmaceuticals, Inc.4 Canadian Myeloma Research Group4 Ipsen4 Vertex Pharmaceuticals Incorporated4 Gilead Sciences4 Centre hospitalier de l'Université de Montréal (CHUM)3 University of Manitoba3 Cytokinetics3 Nuvalent Inc.3 Akero Therapeutics, Inc3 BioMarin Pharmaceutical3 Mount Sinai Hospital, Canada3 Colorado Prevention Center3 Daiichi Sankyo3 Alliance for Clinical Trials in Oncology3 London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's3 Pharvaris Netherlands B.V.3 Biogen3 Children's Hospital of Eastern Ontario3 University of Sydney3 Taiho Oncology, Inc.3 ArriVent BioPharma, Inc.3 Oruka Therapeutics, Inc.3 Exelixis3 Ottawa Heart Institute Research Corporation3 ADARx Pharmaceuticals, Inc.3 Karyopharm Therapeutics Inc3 LEO Pharma3 Genzyme, a Sanofi Company3 Cogent Biosciences, Inc.3 Astria Therapeutics, Inc.3 Acerta Pharma BV3 Institut de Recherches Cliniques de Montreal2 Azafaros B.V.2 Summit Therapeutics2 Bausch Health Americas, Inc.2 Aesculap Biologics, LLC2 Arrowhead Pharmaceuticals2 Alimentiv Inc.2 Unity Health Toronto2 Astellas Pharma Global Development, Inc.2 Sarepta Therapeutics, Inc.2 St. Justine's Hospital2 Ionis Pharmaceuticals, Inc.2 Joseph Broderick, MD2 Swedish Orphan Biovitrum2 Kite, A Gilead Company2 Denali Therapeutics Inc.2 Apogee Therapeutics, Inc.2 Abivax S.A.2 Bluefin Biomedicine, Inc.2 Washington University School of Medicine2 Prilenia2 OncoVerity, Inc.2 Montreal Heart Institute2 Ontario Clinical Oncology Group (OCOG)2 NYU Langone Health2 Alumis Inc2 Turning Point Therapeutics, Inc.2 Nanostics2 SWOG Cancer Research Network2 Icahn School of Medicine at Mount Sinai2 Loxo Oncology, Inc.2 IDEAYA Biosciences2 BioAegis Therapeutics Inc.1 MediLink Therapeutics (Suzhou) Co., Ltd.1 ADC Therapeutics S.A.1 British Columbia Cancer Agency1 Edesa Biotech Inc.1 pharmaand GmbH1 Aragon Pharmaceuticals, Inc.1 Jaeb Center for Health Research1 Tesaro, Inc.1 Gabriela Ilie1 Miltenyi Biomedicine GmbH1 Nektar Therapeutics1 IWK Health Centre1 University of Michigan1 Ocugen1 European Organisation for Research and Treatment of Cancer - EORTC1 Mirati Therapeutics Inc.1 PSC Partners Seeking a Cure1 Sun Pharmaceutical Industries, Inc.1 Priovant Therapeutics, Inc.1 Matthew James1 MediciNova1 Stichting European Myeloma Network1 Tzu-Fei Wang1 Aligos Therapeutics1 Occlutech International AB1 University of Toronto Practice Based Research Network1 Janssen Biotech, Inc.1 The George Institute1 Corxel Pharmaceuticals1 Genmab1 Kymera Therapeutics, Inc.1 Actuate Therapeutics Inc.1 Intellia Therapeutics1 Women's College Hospital1 Brigham and Women's Hospital1 Dr. Rosalie Wang1 Day One Biopharmaceuticals, Inc.1 Portal Therapeutics, Inc.1 AVEO Pharmaceuticals, Inc.1 The University of Queensland1 Lupus Research Alliance1 Parth Patel1 Spyre Therapeutics, Inc.1 Blueprint Medicines Corporation1 Jeffrey Pernica1 H. Lundbeck A/S1 Sir Mortimer B. Davis - Jewish General Hospital1 SonoMotion1 Avidity Biosciences, Inc.1 Northwestern University1 NoNO Inc.1 European Foundation for Study of Chronic Liver Failure1 University of Melbourne1 Horizon Health Network1 KU Leuven1 Dinesh Thavendiranathan1 argenx1 Janssen-Cilag Ltd.1 Apollo Therapeutics Ltd1 McMaster University1 Eupraxia Pharmaceuticals Inc.1 Basilea Pharmaceutica1 Baylor College of Medicine1 Biosensors Europe SA1 Tenaya Therapeutics1 Epineuron Technologies Inc.1 Aerogen Pharma Limited1 Cardiac Dimensions, Inc.1 CeleCor Therapeutics1 Karuna Therapeutics, Inc., a Bristol Myers Squibb company1 Paul Shin1 Neurocrine Biosciences1 Bold Therapeutics, Inc.1 Carl Backes, MD1 X4 Pharmaceuticals1 Centers for Disease Control and Prevention1 CSL Behring1 Children's Hospital of Philadelphia1 Anthos Therapeutics, Inc.1 Dr. Amer Johri1 Parkinson's Foundation1 Laboratoires Thea1 Tyra Biosciences, Inc1 CHU de Quebec-Universite Laval1 Waleed Alqurashi1 TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)1 Arcus Biosciences, Inc.1 CVRx, Inc.1 European Myeloma Network B.V.1 Eric Parent1 Erasmus Medical Center1 NuvOx LLC1 Erasca, Inc.1 DiaMedica Therapeutics Inc1 DalCor Pharmaceuticals1 Weizmann Institute of Science1 Sumitomo Pharma America, Inc.1 Bernie Eigl1 RTOG Foundation, Inc.1 QurAlis Corporation1 K36 Therapeutics, Inc.1 McGill University1 QED Therapeutics, a BridgeBio company1 Cartesian Therapeutics1 Université de Sherbrooke1 Eisai Inc.1 Naveen Poonai1 Viatris Innovation GmbH1 Tanabe Pharma America, Inc.1 Todd C. Lee MD MPH FIDSA1 Nationwide Children's Hospital1 BioNTech SE1 United Therapeutics1 Ultragenyx Pharmaceutical Inc1 Genentech, Inc.1 Apollomics Inc.1 PedAL BCU, LLC1 Exact Sciences Corporation1 Corbus Pharmaceuticals Inc.1 Daniel Coury1 Palisade Bio1 Immunocore Ltd1 Kartos Therapeutics, Inc.1 Eikon Therapeutics1 CHDI Foundation, Inc.1 Conjupro Biotherapeutics, Inc.1 Deciphera Pharmaceuticals, LLC1 Endevica Bio1 Connecticut Children's Medical Center1 Janssen Scientific Affairs, LLC1 Birch BioMed Inc1 Donald Mabbott1 NovoCure GmbH1 Australian & New Zealand Children's Haematology/Oncology Group1 NSABP Foundation Inc1 NS Pharma, Inc.1 Chugai Pharmaceutical1 Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)1 Astellas Gene Therapies1 Protagonist Therapeutics, Inc.1 Heart Rhythm Clinical and Research Solutions, LLC1 University of Maryland, Baltimore1 Nova Scotia Health Authority1 Medtronic Cardiovascular1 Michelle Baczynski1 PharmaMatrix Holdings Ltd1 BlossomHill Therapeutics1 Vedanta Biosciences, Inc.1 St. Jude Children's Research Hospital1 Suzanne Schuh1 Teva Branded Pharmaceutical Products R&D LLC1 Geron Corporation1 Alessandro Doria1 Stanford University1 Madrigal Pharmaceuticals, Inc.1 AtriCure, Inc.1 Treadwell Therapeutics, Inc1 Laval University1 New York Medical College1 UMC Utrecht1 MoonLake Immunotherapeutics AG1 Proteocyte Diagnostics Inc.1 Basking Biosciences, Inc.1 Australasian Gastro-Intestinal Trials Group1 Sanofi Pasteur, a Sanofi Company1 UCB Biopharma SRL1 Alnylam Pharmaceuticals1 American Gastroenterological Association1 Inhibikase Therapeutics1 Weill Medical College of Cornell University1 Prostate Cancer Clinical Trials Consortium1 Syndax Pharmaceuticals1 Merz Pharmaceuticals GmbH1 Endeavor Biomedicines, Inc.1 Indiana University1 Smith & Nephew, Inc.1 Tanja Andrea Gruber1 NervGen Pharma1 Prometei Pain Rehabilitation Center1 Octapharma1 Immatics US, Inc.1 Annexon, Inc.1 Holland Bloorview Kids Rehabilitation Hospital1 Eisai Limited1 Actelion1
Site location
Toronto2818 Montreal1913 Vancouver1187 Calgary1068 Edmonton1018 Ottawa884 London878 Hamilton811 Québec682 Halifax535 Winnipeg454 Sherbrooke264 Kingston254 Kelowna176 Brampton143 Surrey138 Victoria129 St. John's126 Barrie125 Saskatoon125 Chicoutimi100 Moncton92 Mississauga89 Greater Sudbury83 Regina82 Trois-Rivières80 Saint John75 Greenfield Park73 Oshawa73 New Westminster70 Newmarket68 North York64 Markham61 Ajax60 Windsor55 Lévis53 Kitchener49 Fredericton49 Oakville48 Waterloo47 Guelph42 Rimouski39 Burlington37 Peterborough37 Abbotsford British Columbia36 Sarnia34 Red Deer33 Scarborough Village32 Laval30 Cambridge30 Richmond Hill30 Etobicoke26 Vaughan26 Thunder Bay26 Gatineau24 Prince George22 Sault Ste. Marie21 North Vancouver20 Richmond20 Burnaby19 Sherwood Park18 Lethbridge18 Verdun18 Whitby17 Niagara Falls17 North Bay17 Sydney16 St. Catharines14 Stouffville13 Saint-Jérôme13 Saint-Charles-Borromée13 Longueuil13 Stoney Creek12 Concord11 Kentville11 Truro10 Terrebonne10 Penticton10 Courtice9 Mount Royal9 Kamloops9 Mirabel8 Victoriaville8 St. Albert7 Saint Catharines7 Winchester7 Joliette6 Brandon6 Dartmouth6 West Vancouver6 Bridgewater6 Saguenay6 Medicine Hat6 Thornhill6 Brantford5 Pointe-Claire5 Orillia5 Westmount5 Cobourg5 East York5 Nanaimo5 Ontario5 Nova Scotia4 Owen Sound4 Chilliwack4 Montral4 North YORK4 Scarborough4 Boisbriand4 Multiple Locations4 Woodbridge4 Granby4 Langley4 Sainte-Foy4 New Minas3 Canmore3 Dieppe3 Ste-Foy3 Decarie Montreal3 Many Locations3 Grande Prairie3 Winnepeg3 Chatham2 Stratford2 Belleville2 Nepean2 Saint Johns2 Saint-Georges2 Fort McMurray2 Cranbrook2 Hawkesbury2 Dundas2 Sainte-Marie2 Okanagan2 SaintJerome2 Pembroke2 Pierrefonds2 Bedford2 Alberta2 Banff2 Jonquière2 Saint-Laurent2 Edmundston2 Montréal2 Niagara2 Hanover1 Renfrew1 Drummondville1 Maria1 Miramichi1 Penetanguishene1 Norway House1 Baie-Saint-Paul1 La Malbaie1 Edmonton & Calgary1 Multiple1 North Van Couver1 Grand Prairie1 Mississagua1 Saint Isidore1 Bowmanville1 Coxheath1 Lai Chi Kok1 Sioux Lookout1 Wawa1 Piikani Nation1 Flying Dust First Nation1 Ministikwan Lake1 Onion Lake1 Waterhen Lake1 Greenville1 Fleurimont1 Saint Catherines1 Prince Albert1 Calgery1 Frederiction1 Vancouver BC1 Prince Rupert1 Sept-Îles1 Ville-Marie1 Orangeville1 Whistler1 Egypt1 Port Perry1 Newcastle1 Mira Road1 Happy Valley-Goose Bay1 Norris Point1 Woodstock1 High River1 Antigonish Nova Scotia1 Saint Jerome Quebec1 Airdrie1 Burin1 Clarenville1 Hailfax1 Alliston1 Cowansville1 Saint-Hyacinthe1 Montr Al1 Kanata1 Pickering1 Columbia1 Charlottetown1 Dalhousie1 Carbonear1 Cornwall1 Limoges1 Orléans1 Aurora1 Mission1 Dorchester1 Smiths Crossing1 Moose Jaw1 Fort Erie1 Kelowna BC1 Coburg1 Tiny1 Ganges1 Bathurst1 Bouctouche1 Campbellton1 Caraquet1 Grand Falls1 Saint-Quentin1 Pierrefonds-Roxboro1 Edmonton AB1 Montréal1 Châteauguay1 Portage la Prairie1 Denver1 Winnipeg MB1 Brockville1 Montreal, Quebec1 Weston1 Gloucester1 Emo1 Dryden1 Fort Frances1 Lakefield1 Napanee1 Hamitlon1 Laurier1 Hagersville1 Strathroy1 West Hamilton1 Don Mills1 Val-d'Or1
All 248 locations
Target enrolment
to

Trials with a site in Edmonton

1018 of 6553 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Canada
Start
Not yet open
University of Alberta
Not applicable
30
Edmonton
2027-09-01
Not yet open
University of Alberta
Not applicable
75
Edmonton, Toronto
2027-07-01
Not yet open
Insights Into the Continuous Renal Replacement Therapy to Critical Ill Patients
NCT07365111Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury, Renal Dialysis, Critical Illness
University of Alberta
Observational
100,000
Edmonton
2027-03-31
Not yet open
Xo-Motion R Exoskeleton in SCI-Adoption Study
NCT07380516Spinal Cord Injury
University of Alberta
Not applicable
16
Edmonton
2027-03-01
Not yet open
University of Alberta
Not applicable
150
Edmonton
2027-03-01
Recruiting
Birch BioMed Inc
Phase 2/3
70
Edmonton, Hamilton
2027-03
Recruiting
A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients
NCT07898774C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN), Recurrent Glomerular Disease After Kidney Transplantation
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 3
30
Edmonton, Vancouver, London, Toronto, Montreal
2027-01-21
Not yet open
University of Alberta
Phase 1
27
Edmonton, Ottawa, Toronto
2027-01-15
Not yet open
Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL
NCT07301424Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia
University of Alberta
Phase 2
80
Edmonton
2027-01-02
Not yet open
Home Monitoring Study for Surgical Patients
NCT07231653Patient Monitoring, Postoperative Period
University of Alberta
Observational
69
Edmonton
2027-01-01
Not yet open
University of Alberta
Not applicable
554
Edmonton
2027-01-01
Not yet open
Recurrent Laryngeal Nerve Monitoring During Pediatric Aerodigestive Tract and Cardiac Surgery
NCT07604623Unilateral Vocal Cord Paralysis, Unilateral Vocal Cord Paresis
University of Alberta
Not applicable
90
Edmonton
2027-01-01
Not yet open
Ketone Ester for Treatment Of Acute Heart Failure
NCT07434466Acute Heart Failure
University of Alberta
Not applicable
60
Edmonton
2027-01
Not yet open
University of Alberta
Not applicable
252
Edmonton
2027-01
Not yet open
University of Calgary
Phase 3
800
Calgary, Edmonton, Vancouver, Winnipeg
2026-12-15
Not yet open
University of Alberta
Phase 4
600
Edmonton
2026-12-01
Not yet open
Canadian Myeloma Research Group
Phase 1
108
Edmonton, Halifax, London, Ottawa, Toronto, Montreal
2026-12
Not yet open
AHS Cancer Control Alberta
Phase 2
250
Edmonton
2026-12
Not yet open
Institut de Recherches Cliniques de Montreal
Not applicable
63
Edmonton, Hamilton, Montreal
2026-12
Not yet open
reALIGNing Circadian Rhythm and Promoting Sleep in the Intensive Care Unit
NCT07886567Sleep, Circadian Dysregulation, ICU, Delirium in Intensive Care Unit
University of Alberta
Early Phase 1
50
Edmonton
2026-11-30
Not yet open
University of Alberta
Not applicable
1,520
Edmonton
2026-11-01
Not yet open
Cardiopulmonary Complications of Electronic Cigarettes
NCT07924007Electronic Cigarette Use, Cannabis Use
University of Alberta
Not applicable
480
Edmonton
2026-11-01
Not yet open
Yeast Protein for Muscle Mass
NCT07561619Healthy Adult Participants
University of Alberta
Phase 2/3
72
Edmonton
2026-11
Not yet open
University of Alberta
Not applicable
78
Edmonton
2026-10-30
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Edmonton, Red Deer, Vancouver, Moncton, Truro, London, Mississauga, North York
2026-10-26
Not yet open
University of Alberta
Phase 4
35
Edmonton
2026-10-15
Not yet open
University of Alberta
Not applicable
50
Edmonton
2026-10-15
Recruiting
The PROTECT-HIE Pilot Trial
NCT07406477Hypoxic-ischemic Encephalopathy (HIE)
DrugDobutamine
University of Alberta
Phase 2
40
Edmonton
2026-10-13
Recruiting
Trained vs. Untrained: Lower Extremity Pressure Changes
NCT07897357Trained Athletes, Untrained
University of Alberta
Not applicable
200
Edmonton
2026-10-09
Not yet open
National Surveillance and Prevention of Neonatal VAP
NCT07109791Ventilator-Associated Pneumonia (VAP), Neonatal, Bronchopulmonary Dysplasia (BPD), Antibiotic-Resistant Organisms (AROs), Health-Care Associated Infection (HAI)
University of Alberta
Observational
1,500
Edmonton
2026-10-01
Not yet open
Machine Learning and Artificial Intelligence Algorithms to Optimize the Performance and Delivery of Acute Dialysis
NCT07312929Renal Dialysis, Renal Replacement Therapy, Renal Diseases, Quality Health Care
University of Alberta
Observational
7,500
Calgary, Edmonton, Fort McMurray, Grand Prairie, Lethbridge, Medicine Hat, Red Deer, St. Albert
2026-10-01
Recruiting
Evaluating AI for the Translation of KM Resources
NCT07666399Communication Research
University of Alberta
Not applicable
576
Edmonton
2026-10
Not yet open
Breaking the Cycle: Real-Time Family Oral Microbial Transmission Patterns as Intervention Targets
NCT07674888Dental Caries, Periodontitis, Oral Microbiome, Bacterial Transmission
University of Alberta
Not applicable
225
Edmonton
2026-09-30
Recruiting
Corbus Pharmaceuticals Inc.
Phase 3
260
Edmonton, London, Montreal, Ottawa, Regina
2026-09-29
Recruiting
NervGen Pharma
Phase 3
150
Edmonton, Vancouver
2026-09-28
Not yet open
University of Manitoba
Not applicable
90
Edmonton, Winnipeg, Saskatoon
2026-09-23
Not yet open
University of Alberta
Not applicable
50
Edmonton
2026-09-21
Recruiting
Deep Brain Reorienting for Posttraumatic Stress Disorder
NCT07840417Posttraumatic Stress Disorder (PTSD), Posttraumatic Stress Symptom
University of Alberta
Not applicable
50
Edmonton
2026-09-21
Recruiting
AstraZeneca
Phase 3
1,330
Calgary, Edmonton, Abbotsford British Columbia, Brampton, Kitchener, North York, Ottawa, Toronto
2026-09-15
Not yet open
University of Alberta
Not applicable
180
Edmonton
2026-09-15
Not yet open
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism
NCT07284745Irritability Associated With Autism Spectrum Disorder
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
176
Airdrie, Edmonton, Kingston, Toronto, Montreal
2026-09-11
Recruiting
Bristol-Myers Squibb
Phase 3
850
Edmonton, Vancouver, Montreal, Regina
2026-09-08
Not yet open
Feasibility Evaluation of WEAR-IT for Hand Therapy After Stroke
NCT07698067Stroke (6 Months or More After Onset)
Dr. Rosalie Wang
Not applicable
44
Edmonton, Toronto
2026-09-01
Recruiting
AstraZeneca
Phase 3
2,800
Calgary, Edmonton, Winnipeg, Halifax, Brampton, Greater Sudbury, London, Mississauga
2026-09-01
Recruiting
Spyre Therapeutics, Inc.
Phase 2
150
Edmonton, Surrey, Winnipeg, Barrie, Markham, Richmond Hill, Québec, Saskatoon
2026-09
Not yet open
University of Alberta
Not applicable
98
Edmonton
2026-09
Recruiting
AHS Cancer Control Alberta
Phase 2
58
Edmonton
2026-08-31
Recruiting
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07845487Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis
DrugPALI-2108
Palisade Bio
Phase 2
204
Calgary, Edmonton, Greater Sudbury, London, Scarborough Village, Montreal
2026-08-28
Recruiting
Canadian Cancer Trials Group
Phase 2
40
Calgary, Edmonton, Vancouver, Hamilton, Toronto
2026-08-24
Recruiting
Novo Nordisk A/S
Phase 3
1,778
Calgary, Edmonton, Red Deer, Kelowna, Sydney, Sarnia, Stouffville, Toronto
2026-08-24
Recruiting
AstraZeneca
Phase 3
7,000
Calgary, Edmonton, Vancouver, Winnipeg, Saint John, London, Scarborough Village, Toronto
2026-08-21
Recruiting
Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer
NCT06337695IrAE, Immune-related Adverse Event, Diarrhea, Colitis
DrugVedolizumab
AHS Cancer Control Alberta
Phase 2/3
36
Calgary, Edmonton
2026-08-13
Recruiting
ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
NCT07687056Stroke, Acute Ischemic, Endovascular Thrombectomy, Acute Ischemic Stroke AIS
DrugTenecteplase
University of Calgary
Phase 3
1,500
Calgary, Edmonton, Kelowna, New Westminster, Vancouver, Winnipeg, Greater Sudbury, Ottawa
2026-08-11
Recruiting
Electronic Health Record Augmented LDL-Cholesterol Optimization and Control Via Active Lipid Engagement (EHR-LOCALE): A Quality Improvement Implementation Study
NCT07685639ACS (Acute Coronary Syndrome), Hyperlipidemia, Dyslipidemia, Low-Density-Lipoprotein-cholesterol Level
University of Alberta
Not applicable
2,000
Edmonton
2026-08-10
Recruiting
Edesa Biotech Inc.
Phase 2
80
Edmonton, Guelph, Newmarket, Toronto
2026-08-05
Recruiting
University of Alberta
Not applicable
150
Calgary, Edmonton
2026-08-03
Not yet open
University of Alberta
Not applicable
30
Edmonton
2026-08-01
Recruiting
Eisai Limited
Observational
400
Calgary, Edmonton, Vancouver, Victoria, Kingston, London, Mississauga, Ottawa
2026-07-30
Recruiting
Boehringer Ingelheim
Phase 3
448
Calgary, Edmonton, London, Toronto
2026-07-27
Recruiting
Novartis Pharmaceuticals
Phase 3
710
Edmonton, London, Montreal, Québec
2026-07-10
Recruiting
Prilenia
Phase 3
400
Calgary, Edmonton, Vancouver, Toronto, Montreal
2026-07-01
Recruiting
University of Alberta
Not applicable
20
Edmonton
2026-07-01
Recruiting
Connecting Today to Combat Social Isolation and Loneliness
NCT07182019Dementia in Nursing Home, Family, Remote Visits
University of Alberta
Not applicable
320
Edmonton
2026-06-09
Recruiting
University of Alberta
Not applicable
200
Edmonton
2026-06-02
Recruiting
Bayer
Phase 3
117
Edmonton, Vancouver, London, Toronto, Montreal, Saskatoon
2026-06-01
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Calgary, Edmonton, Oshawa, Toronto
2026-05-31
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07599813Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic
Apollo Therapeutics Ltd
Phase 2
280
Calgary, Edmonton, Mississauga, Toronto, Sherbrooke, Saskatoon
2026-05-28
Recruiting
Pfizer
Phase 2
24
Edmonton, Winnipeg, Québec
2026-05-28
Recruiting
University of Alberta
Not applicable
25
Edmonton
2026-05-26
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Edmonton, Vancouver, Kentville, Barrie, Hamilton, London, Toronto, Montreal
2026-05-23
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Edmonton, Vancouver, Halifax, Kentville, London, Mississauga, Toronto, Vaughan
2026-05-22
Recruiting
Canadian Cancer Trials Group
Observational
1,000
Calgary, Edmonton, Kelowna, Prince George, Vancouver, Victoria, Saint John, Hamilton
2026-05-15
Recruiting
Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
NCT07272837Type 2 Diabetes, Obesity, Semaglutide, GLP-1
University of Alberta
Observational
50
Edmonton
2026-05-15
Recruiting
Ipsen
Phase 3
350
Calgary, Edmonton, Vancouver, Winnipeg, Halifax, Brampton, London, North Bay
2026-05-14
Recruiting
University of Alberta
Phase 4
100
Edmonton, St. Albert
2026-05-11
Recruiting
AstraZeneca
Phase 3
670
Edmonton, Halifax, Hamilton, Toronto, Montreal
2026-05-04
Recruiting
Improving the Care of Incontinence-Associated Dermatitis (IAD) Using a Beta-Glucan Cream as a Hydrating and Soothing Agent
NCT07524439Fecal Incontinence, Urinary Incontinence, Diaper Rash, Irritant Contact Dermatitis Caused by Faeces
University of Alberta
Not applicable
60
Edmonton
2026-05-01
Not yet open
Mindfulness-Based Intervention for Pediatric Mild Traumatic Brain Injury
NCT07272941Concussions, Mild Traumatic Brain Injury, Concussion, Concussion Mild
Children's Hospital of Eastern Ontario
Not applicable
362
Edmonton, Ottawa, Toronto, Vancouver, Montreal
2026-05
Recruiting
Portal Therapeutics, Inc.
Observational
50
Edmonton
2026-04-30
Recruiting
University of Alberta
Not applicable
43
Edmonton
2026-04-30
Recruiting
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
DrugsAsciminib single agent·ABL001
Novartis Pharmaceuticals
Phase 2
50
Edmonton, Montreal
2026-04-28
Recruiting
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 3
500
Edmonton, Montreal
2026-04-24
Recruiting
Inhibikase Therapeutics
Phase 3
486
Edmonton
2026-04-23
Recruiting
Janssen Research & Development, LLC
Phase 3
530
Edmonton, Vancouver, Hamilton, London, Oshawa, Toronto, Montreal
2026-04-21
Recruiting
Pediatric Evaluation and Registry for Liver Cholestasis in Canada
NCT07411716PFIC - Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome (ALGS), Cholestasis, Intrahepatic
Children's Hospital of Eastern Ontario
Observational
220
Calgary, Edmonton, Vancouver, Winnipeg, St. John's, Halifax, Hamilton, London
2026-04-21
Recruiting
PromotIng Optimal Treatment for Community-acquired PNeumonia in EmErgency Rooms
NCT07099976Community-Acquired Pneumonia (CAP), Pneumonia
Jeffrey Pernica
Not applicable
698
Calgary, Edmonton, Vancouver, Hamilton, Ottawa, Toronto
2026-04-15
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
400
Calgary, Edmonton, Kingston, Toronto, Montreal
2026-04-07
Recruiting
Topical Diclofenac vs.Oral Ibuprofen for MSK Pain in Children
NCT07145645Musculoskeletal Injury, Pediatrics, Sprain and Strain of Ankle, Sprain Knee
DrugsORA-Blend·Ibuprofen
University of Calgary
Phase 3
60
Calgary, Edmonton
2026-04-02
Recruiting
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
ADARx Pharmaceuticals, Inc.
Phase 3
90
Edmonton, Ottawa, Montreal
2026-04-02
Not yet open
The Hospital for Sick Children
Not applicable
30
Toronto, Edmonton
2026-04-01
Recruiting
Arrowhead Pharmaceuticals
Phase 2
36
Vancouver, Calgary, Edmonton, Hamilton, Québec, Saskatoon
2026-03-30
Recruiting
Bristol-Myers Squibb
Phase 1/2
474
Calgary, Edmonton, Montreal, Québec
2026-03-26
Recruiting
Improving Health Outcomes With Kefir
NCT06695221Systemic Inflammatory Response, Diabetes Mellitus, Type 2, Cardiovascular Diseases
University of Alberta
Not applicable
156
Edmonton
2026-03-24
Recruiting
Priovant Therapeutics, Inc.
Phase 2/3
342
Edmonton, Guelph, London, Toronto
2026-03-19
Active, closed
Oruka Therapeutics, Inc.
Phase 2
160
Edmonton, Surrey, Barrie, London, North Bay, Peterborough, Toronto, Waterloo
2026-03-19
Recruiting
University of Alberta
Not applicable
40
Edmonton
2026-03-15
Recruiting
University of Sydney
Phase 3
540
Calgary, Edmonton, Vancouver, Winnipeg, Halifax, London, Toronto, Montreal
2026-03-13
Recruiting
Incyte Corporation
Phase 3
700
Edmonton, Hamilton, Toronto, Greenfield Park, Lévis, Saint-Jérôme, Saskatoon
2026-03-05
Recruiting
Fecal Microbiota Transplantation in an Expanded Ulcerative Colitis Population
NCT07401680Ulcerative Colitis, Inflammatory Bowel Diseases, Clostridioides Difficile Infection
University of Alberta
Phase 1
85
Calgary, Edmonton
2026-03-01
Recruiting
Boehringer Ingelheim
Phase 2
30
Edmonton
2026-02-27
Recruiting
Understanding the Health Effect of a Bioactive Peptide From Egg: A Pilot Study
NCT06555393High Blood Sugar, High Blood Pressure, Overweight and Obesity
University of Alberta
Phase 1
28
Edmonton
2026-02-25
Recruiting
Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD
NCT07187830Chronic Kidney Disease in Type 2 Diabetes, Obesity & Overweight
University of Alberta
Observational
52
Edmonton
2026-02-23
Recruiting
Oruka Therapeutics, Inc.
Phase 2
240
Edmonton, Surrey, Fredericton, Ajax, London, Markham, Peterborough, Toronto
2026-02-23
Recruiting
University of Alberta
Phase 2
30
Edmonton, St. Albert
2026-02-05
Recruiting
Eli Lilly and Company
Phase 3
300
Calgary, Chicoutimi, Edmonton, London, Ottawa, Québec, Vancouver
2026-02-05
Recruiting
University of Alberta
Not applicable
8
Edmonton
2026-02-05
Recruiting
AstraZeneca
Phase 3
2,130
Edmonton, Abbotsford British Columbia, Vancouver, Winnipeg, Moncton, Barrie, Brampton, Ottawa
2026-02-03
Recruiting
Prilenia
Phase 3
500
Montreal, Edmonton, Hamilton
2026-02-01
Recruiting
University of Alberta
Not applicable
30
Edmonton
2026-01-26
Recruiting
IDEAYA Biosciences
Phase 3
520
Edmonton, Toronto
2026-01-25
Recruiting
Sanofi
Phase 3
751
Edmonton, Hamilton, London, New Westminster, Toronto
2026-01-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Calgary, Edmonton, Halifax, London, Toronto, Montreal, Québec, Sherbrooke
2026-01-19
Recruiting
Vorasidenib Maintenance for IDH Mutant Astrocytoma
NCT06809322IDH-mutant Grade 2 or 3 Astrocytoma
DrugVorasidenib
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
468
Calgary, Edmonton, Vancouver, Winnipeg, Halifax, Hamilton, Kingston, London
2026-01-16
Recruiting
Sanofi
Phase 3
751
Toronto, Edmonton, Hamilton, London, New Westminster
2026-01-16
Recruiting
Boehringer Ingelheim
Phase 3
400
Edmonton, Toronto
2026-01-16
Recruiting
Eli Lilly and Company
Phase 3
150
Calgary, Edmonton, Vancouver
2026-01-12
Recruiting
St. Justine's Hospital
Phase 1/2
50
Calgary, Edmonton, Vancouver, Winnipeg, London, Ottawa, Toronto, Montreal
2026-01-12
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Calgary, Edmonton, London, Toronto, Windsor, Chicoutimi, Greenfield Park, Montreal
2026-01-06
Recruiting
Biogen
Phase 2
81
Edmonton, Vancouver
2026-01-05
Not yet open
University of British Columbia
Not applicable
914
Edmonton, Barrie, London, North York, Vancouver
2026-01-01
Recruiting
AstraZeneca
Phase 3
1,100
Edmonton, Hamilton, Kingston, Montreal, Québec
2025-12-29
Active, closed
UCB Biopharma SRL
Phase 2
165
Edmonton, Hamilton, Toronto, Vancouver
2025-12-29
Recruiting
Taiho Oncology, Inc.
Phase 3
360
Edmonton, Brampton, London, Toronto
2025-12-22
Recruiting
ArriVent BioPharma, Inc.
Phase 3
480
Calgary, Edmonton, Vancouver, Brampton, Ottawa, Toronto
2025-12-17
Recruiting
Canadian Cancer Trials Group
Phase 3
320
Edmonton, Winnipeg, Toronto
2025-12-16
Recruiting
AstraZeneca
Phase 2
230
Edmonton, Vancouver, Victoria, Halifax, Hamilton, London, Montreal, Québec
2025-12-10
Active, closed
Boehringer Ingelheim
Phase 3
135
Edmonton, Vancouver, Toronto, Saskatoon
2025-12-09
Recruiting
Incyte Corporation
Phase 3
466
Calgary, Edmonton, London, Toronto, Montreal
2025-12-09
Recruiting
Bristol-Myers Squibb
Phase 3
366
Edmonton, Winnipeg, St. John's, London, Richmond Hill, Toronto, Montreal
2025-12-03
Recruiting
Feasibility and Pilot Testing of "My Heart and CKD" Online Shared Decision Aid
NCT06920927Chronic Kidney Disease, Coronary Artery Disease
University of Calgary
Not applicable
220
Calgary, Edmonton
2025-12-01
Recruiting
University of Alberta
Not applicable
50
Edmonton
2025-12-01
Recruiting
Michelle Baczynski
Not applicable
780
Calgary, Edmonton, Vancouver, Hamilton, London, Toronto, Montral, Montreal
2025-12-01
Not yet open
Stanford University
Not applicable
62
Edmonton
2025-12
By invitation
Pre-op Exercise for AIS Surgery
NCT07516574Adolescent Idiopathic Scoliosis (AIS)
Eric Parent
Not applicable
40
Edmonton
2025-11-26
By invitation
Celldex Therapeutics
Phase 3
1,370
Edmonton, Hamilton, Markham, North Bay, Toronto, Windsor, Kingston, Québec
2025-11-25
Active, closed
Kymera Therapeutics, Inc.
Phase 2
200
Calgary, Edmonton, Kelowna, Surrey, Markham, Ottawa, Richmond Hill, Toronto
2025-11-24
Recruiting
Bayer
Phase 3
111
Edmonton, Vancouver, London, Toronto, Montreal, Saskatoon
2025-11-19
Recruiting
University of Alberta
Phase 2/3
300
Edmonton, Vancouver, Toronto, Montreal, Sherbrooke
2025-11-18
Active, closed
Pfizer
Phase 2
128
Calgary, Edmonton, Red Deer, Newmarket, Ottawa, Toronto, Québec
2025-11-13
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Calgary, Edmonton, Burnaby, Vancouver, Halifax, Ottawa, Lévis, Montreal
2025-11-11
Recruiting
University of Alberta
Observational
73
Edmonton
2025-11-11
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Edmonton, Vancouver, London, Ottawa, Toronto
2025-11-10
Recruiting
Sanofi
Phase 2
208
Edmonton, Sherwood Park, Kelowna, Hamilton, Toronto, Québec
2025-11-06
Active, closed
Bluefin Biomedicine, Inc.
Phase 2/3
210
Edmonton, Richmond Hill, Toronto, Québec
2025-11-03
Recruiting
BCI@Home: Brain Computer Interface Solutions to Enable Youth Living With Severe Disabilities
NCT07073378Cerebral Palsy, Pediatric Stroke, Genetic Condition, Acquired Brain Injury (Including Stroke)
University of Calgary
Not applicable
18
Calgary, Edmonton
2025-11-01
Recruiting
Fish Oil, Metformin and Heart Health in PCOS
NCT06424860PCOS, Cardiovascular Disease, Atherosclerotic Cardiovascular Disease, Atherosclerotic Plaque
DrugMetformin
University of Alberta
Phase 1
146
Edmonton
2025-11-01
Not yet open
Single-dose Prophylactic INdomethacin in Extremely Preterm Infants
NCT06572917Extreme Prematurity, Intraventricular Hemorrhage, Morbidity;Newborn
DrugIndomethacin
University of British Columbia
Phase 2
500
Calgary, Edmonton, New Westminster, Vancouver, Halifax, Toronto, Montreal, Québec
2025-11-01
Recruiting
Pfizer
Phase 2
200
Edmonton, Red Deer, Mississauga, Niagara Falls, Ottawa, Montreal, Québec
2025-10-30
Recruiting
PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury
NCT06819592All-cause Mortality, Quality of Life, Disability, Intellectual, Neurological Disorder
The George Institute
Phase 3
3,300
Edmonton
2025-10-30
Recruiting
Regeneron Pharmaceuticals
Phase 2
1,200
Edmonton, Victoria, Moncton, Greater Sudbury, Hamilton, Oshawa, Scarborough Village, Longueuil
2025-10-20
Recruiting
Pharvaris Netherlands B.V.
Phase 3
48
Edmonton
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
4,500
Calgary, Chicoutimi, Edmonton, Halifax, London, North Bay, Québec, Toronto
2025-10-15
Recruiting
University of Alberta
Not applicable
600
Edmonton
2025-10-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Edmonton, Toronto
2025-10-08
Recruiting
Suzanne Schuh
Phase 3
192
Calgary, Edmonton, Hamilton, Ottawa, Toronto, Montreal
2025-10-08
Recruiting
Sotatercept in Pulmonary Arterial Hypertension
NCT07140484Pulmonary Artery Hypertension
DrugSotatercept
University of Alberta
Phase 4
27
Edmonton
2025-10-06
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Edmonton, Vancouver, Kentville, Barrie, London, Oakville, Toronto, Montreal
2025-10-03
Recruiting
Novartis Pharmaceuticals
Phase 3
300
Edmonton, Hamilton, London, Newmarket, Montreal, Québec
2025-10-03
Not yet open
Ottawa Hospital Research Institute
Phase 2
168
Edmonton, Hamilton, Ottawa, Toronto, Montreal, Québec
2025-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
896
Edmonton, Vancouver, Kentville, Barrie, London, Mississauga, Oakville, Toronto
2025-10-01
By invitation
Astria Therapeutics, Inc.
Phase 3
145
Edmonton
2025-10-01
Recruiting
Sanofi
Phase 3
980
Oakville, Brampton, Edmonton, Greater Sudbury, Hamilton, London, Montreal, New Westminster
2025-10-01
Recruiting
Effectiveness of NOA OATMAD
NCT07111962Obstructive Sleep Apnea
University of Alberta
Observational
150
Edmonton
2025-09-30
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Edmonton, Ottawa, Toronto, Montreal
2025-09-30
Recruiting
Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome
NCT06776783Respiratory Distress Syndrome, Pre-term Infants
Aerogen Pharma Limited
Phase 3
520
Edmonton, Halifax, Hamilton, Ottawa, Toronto, Québec
2025-09-24
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
Calgary, Edmonton, Kelowna, Nanaimo, Surrey, Winnipeg, St. John's, Ajax
2025-09-22
Recruiting
LEO Pharma
Phase 2
135
Calgary, Edmonton, Surrey, Winnipeg, Fredericton, Hamilton, Markham, Waterloo
2025-09-11
Recruiting
AbbVie
Observational
700
Calgary, Edmonton, Winnipeg, Ajax, Belleville, Hamilton, London, Markham
2025-09-09
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Calgary, Edmonton, Hamilton, London, Montreal, Sherbrooke, Toronto, Vancouver
2025-09-08
Recruiting
AbbVie
Observational
2,795
Calgary, Edmonton, Fredericton, Barrie, London, Markham, Richmond Hill, Pointe-Claire
2025-09-02
Recruiting
Wichitasowin: Indigenous Patient Navigator for Young Adults Study
NCT06443190Chronic Diseases in Adolescence
University of Alberta
Not applicable
20
Edmonton
2025-09-01
Recruiting
University of Alberta
Not applicable
5
Edmonton
2025-09-01
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Edmonton, Ottawa, Montreal
2025-08-28
Recruiting
Basilea Pharmaceutica
Phase 3
234
Edmonton, Hamilton, London, Ottawa, Toronto, Vancouver
2025-08-26
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
DrugsEmpasiprubart·IVIG
argenx
Phase 3
218
Calgary, Vancouver, Edmonton
2025-08-22
Recruiting
Amgen
Phase 3
11,000
Calgary, Edmonton, New Westminster, Surrey, Vancouver, Victoria, Brampton, Burlington
2025-08-22
Recruiting
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT06958328Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
DrugsIrinotecan Sucrosofate·Onivyde·Nal-IRI·Lederfolin
NRG Oncology
Phase 3
356
Edmonton
2025-08-21
Recruiting
Novo Nordisk A/S
Phase 4
586
Calgary, Edmonton, New Westminster, Winnipeg, Moncton, Brampton, Burlington, Concord
2025-08-15
Active, closed
GlaxoSmithKline
Phase 2
168
Edmonton, Vancouver, London, Toronto
2025-08-06
Recruiting
Sun Pharmaceutical Industries, Inc.
Phase 3
355
Calgary, Edmonton, Red Deer, Kelowna, Surrey, Markham, Newmarket, Toronto
2025-08-05
Recruiting
Pfizer
Phase 3
400
Edmonton, Ottawa, Toronto, Montreal, Québec
2025-08-05
Recruiting
Eli Lilly and Company
Phase 1
36
Calgary, Edmonton, London, Montreal, Toronto
2025-08-05
Recruiting
AstraZeneca
Phase 3
800
Edmonton, Winnipeg, Hamilton, Kingston, Montreal
2025-08-01
Recruiting
Effect of Hi-OxSR for the Treatment of Post COVID Condition
NCT06928506Long COVID, Post COVID-19 Condition, Post Acute Sequelae of COVID-19
University Health Network, Toronto
Not applicable
120
Edmonton, Toronto, Sherbrooke
2025-08-01
Recruiting
Amgen
Phase 1
434
Edmonton, Toronto, Montreal
2025-07-31
Recruiting
Ultra-Early Gamma Knife Stereotactic Radiosurgery for TN
NCT06949436Trigeminal Neuralgia (TN)
University of Alberta
Phase 2
80
Edmonton
2025-07-30
Recruiting
AbbVie
Phase 3
120
Calgary, Edmonton, London
2025-07-28
Recruiting
The Canadian Lung Outcomes in Users of Vaping Devices Study
NCT06819969Small Airways Diseases, Vaping, Vaping Related Disorder, Vaping Teens
University of British Columbia
Observational
500
Edmonton, Vancouver, Hamilton, Ottawa, Toronto, Sherbrooke
2025-07-25
Active, closed
Amgen
Phase 3
12,800
Edmonton, Vancouver, Victoria, Moncton, Brampton, Cambridge, North York, Scarborough Village
2025-07-25
Active, closed
Oruka Therapeutics, Inc.
Phase 2
80
Edmonton, Surrey, Hamilton, London, Markham, Peterborough, Toronto, Waterloo
2025-07-18
Recruiting
Matthew James
Phase 2
698
Calgary, Edmonton
2025-07-16
Active, closed
Aligos Therapeutics
Phase 2
200
Edmonton, Ottawa, Toronto, Vancouver
2025-07-15
Recruiting
Feasibility Trial for a Right Ventricular Failure Platform Trial
NCT06570473Pulmonary Hypertension, Right Ventricular Dysfunction, Right Heart Failure
DrugsRanolazine·Dapagliflozin
University of Alberta
Phase 2
30
Calgary, Edmonton, Vancouver, London, Ottawa
2025-07-15
Active, closed
Bluefin Biomedicine, Inc.
Phase 2
225
Calgary, Edmonton, Mississauga, Richmond Hill, Montreal, Saskatoon
2025-07-15
By invitation
University of Alberta
Not applicable
12
Edmonton
2025-07-14
Recruiting
RCT of Mind-body in Long COVID and Myalgic Encephalomyelitis
NCT06933173Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
University of Alberta
Not applicable
200
Calgary, Edmonton
2025-07-10
Recruiting
Adapting Rehabilitation Delivery for Maximum Impact at Home-2 (ReDI-2)
NCT07055113Knee Osteoarthritis, Hip Osteoarthritis
University of Alberta
Not applicable
270
Edmonton
2025-07-09
By invitation
Non-invasive Therapy to Drive Nerve Regeneration
NCT05848778Peripheral Nerve Injuries
University of Alberta
Not applicable
80
Edmonton
2025-07-01
Recruiting
University of Alberta
Phase 2
60
Edmonton
2025-07-01
Recruiting
Azafaros B.V.
Phase 3
147
Calgary, Edmonton, Montreal
2025-06-30
Recruiting
Azafaros B.V.
Phase 3
72
Calgary, Edmonton, Montreal
2025-06-30
By invitation
MoonLake Immunotherapeutics AG
Phase 3
835
Calgary, Edmonton, Sherwood Park, Winnipeg, Fredericton, Barrie, Guelph, London
2025-06-27
Recruiting
AstraZeneca
Phase 2
987
Edmonton, Winnipeg, Truro, Ajax, Burlington, Guelph, Hamilton, Stoney Creek
2025-06-27
Recruiting
Eli Lilly and Company
Phase 3
290
Edmonton, London, Montreal, Ottawa, Vancouver
2025-06-26
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Edmonton, Winnipeg, Brampton, Cambridge, Newmarket, North York, Peterborough, Sarnia
2025-06-25
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Edmonton, Vancouver, Lévis, Montreal
2025-06-23
Recruiting
University of Alberta
Phase 3
30
Edmonton
2025-06-23
By invitation
BioMarin Pharmaceutical
Phase 3
140
Edmonton, Toronto, Montreal
2025-06-20
Active, closed
AbbVie
Phase 3
573
Calgary, Edmonton, Barrie, Brampton, Oakville, Toronto, Montreal, Québec
2025-06-17
Active, closed
Incyte Corporation
Phase 3
159
Calgary, Edmonton, Surrey, Vancouver, Winnipeg, Hamilton, Toronto, Montreal
2025-06-17
Active, closed
Incyte Corporation
Phase 3
573
Edmonton, Winnipeg, Fredericton, Hamilton, London, Markham, Mississauga, Saskatoon
2025-06-12
Recruiting
BeOne Medicines
Phase 3
630
Calgary, Edmonton, Vancouver, Winnipeg, St. John's, Ottawa, Toronto, Montreal
2025-06-11
Recruiting
Shorter and Safer Treatment Regimens for Latent TB
NCT06498414Tuberculosis Infection, Latent
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 2/3
1,800
Calgary, Edmonton, Vancouver, Winnipeg, Ottawa, Toronto, Montreal
2025-06-10
Recruiting
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
NCT07038200Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1
DrugDel-brax
Avidity Biosciences, Inc.
Phase 3
200
Calgary, Edmonton, Ottawa, Montreal
2025-06-10
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
156
London, Montreal, Edmonton, Vancouver
2025-06-10
Active, closed
Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD
NCT06969573COPD (Chronic Obstructive Pulmonary Disease)
University of Alberta
Phase 2
20
Edmonton
2025-06-05
Recruiting
Celgene
Phase 2
200
Edmonton, London, Ottawa, Toronto, Lévis, Montreal
2025-06-05
Recruiting
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
NCT06891443Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders
DrugSepofarsen
Laboratoires Thea
Phase 3
32
Edmonton, Toronto
2025-06-04
Recruiting
University of Alberta
Not applicable
69
Edmonton
2025-06-03
Recruiting
COgnitioN With VERiciGuat Evaluation in Heart Failure
NCT06601465Heart Failure, Cognitive Impairment
DrugVericiguat
University of Alberta
Phase 2
120
Calgary, Edmonton, Ottawa, Montreal
2025-06-03
Recruiting
University of Alberta
Observational
30
Edmonton
2025-06-01
Not yet open
University of Calgary
Phase 3
2,170
Calgary, Edmonton, Vancouver, Halifax
2025-06-01
By invitation
University of Alberta
Observational
500
Edmonton
2025-06-01
Recruiting
Canada-wide Implementation of a Virtual Sexual Health and Rehabilitation eClinic (SHAReClinic) for Prostate Cancer Patients and Their Partners
NCT06877598Prostate Cancer, Sexual Dysfunction, Physiological, Sexual Dysfunction, Psychological, Sexual Dysfunction
University Health Network, Toronto
Observational
575
Vancouver, Winnipeg, Barrie, Edmonton, Kingston, London, Mississauga, Ottawa
2025-06-01
Recruiting
National Cancer Institute (NCI)
Phase 2
222
Calgary, Edmonton, Vancouver, Winnipeg, Halifax, Hamilton, Toronto, Montreal
2025-05-30
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Edmonton, London, Toronto, Montreal
2025-05-30
Recruiting
Canadian Cancer Trials Group
Phase 3
830
Edmonton, Vancouver, Winnipeg, Saint John, Greater Sudbury, Hamilton, Kingston, Kitchener
2025-05-28
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
450
Edmonton, Vancouver, Toronto, Montreal
2025-05-19
Recruiting
University of Calgary
Not applicable
1,055
Calgary, Edmonton, High River, Red Deer
2025-05-16
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Edmonton, Hamilton, Markham, Montreal, Verdun
2025-05-16
Recruiting
Corxel Pharmaceuticals
Phase 2/3
740
Edmonton, Kingston, Winnipeg
2025-05-15
Recruiting
Apogee Therapeutics, Inc.
Phase 2
350
Calgary, Edmonton, Vancouver, Fredericton, Ajax, Markham, Mississauga, Ottawa
2025-05-14
Recruiting
University of Alberta
Phase 3
1,284
Edmonton, Vancouver, Toronto, Montréal
2025-05-08
Recruiting
University of Alberta
Phase 2/3
10
Edmonton
2025-05-07
Recruiting
Joseph Broderick, MD
Phase 3
350
Calgary, Edmonton, Vancouver, Winnipeg, Hamilton, Ottawa, Toronto, Montreal
2025-05-06
Recruiting
AstraZeneca
Phase 3
1,220
Edmonton, Halifax, Barrie, Brampton, Cambridge, Ottawa, Toronto, Montreal
2025-05-06
Recruiting
Takeda
Phase 3
225
Edmonton, Vancouver, Halifax, London, Toronto
2025-05-06
Recruiting
Paul Shin
Observational
40
Edmonton
2025-05-01
Recruiting
University of Alberta
Phase 2
50
Edmonton
2025-05-01
Recruiting
Suture Lid Spring for Lid Closure in Patients With Facial Nerve Palsy
NCT06895902Facial Nerve Palsy, Corneal Exposure, Paralytic Lagophthalmos
University of Alberta
Early Phase 1
10
Edmonton
2025-04-28
Recruiting
Endevica Bio
Phase 2
120
Edmonton
2025-04-28
Recruiting
AbbVie
Phase 2
390
Calgary, Edmonton, London, Toronto, Montreal
2025-04-24
Recruiting
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
NCT06401330Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor, Stage IV Mixed Cell Type Kidney Wilms Tumor
DrugsDactinomycin·Vincrystine·Cytoxan·Paraplatin
Children's Oncology Group
Phase 3
1,656
Calgary, Edmonton, Winnipeg, Halifax, Hamilton, London, Ottawa, Toronto
2025-04-15
By invitation
Clinical Utility of ClarityDX Prostate
NCT06678828Prostate Cancer, Prostate Cancer Screening Decision, Prostate Cancer Screening
Nanostics
Not applicable
1,450
Calgary, Edmonton, Vancouver, Winnipeg, Toronto
2025-04-14
Recruiting
Physiotherapy Dry Needling Accuracy
NCT06845969Dry Needling, Physiotherapy
University of Alberta
Not applicable
60
Edmonton
2025-04-10
Recruiting
AstraZeneca
Phase 3
830
Edmonton, Kelowna, Cambridge, Newmarket, Toronto, Québec, Saint-Jérôme
2025-04-10
Recruiting
Hoffmann-La Roche
Phase 3
450
Calgary, Edmonton, Winnipeg, Moncton, Ottawa, Sault Ste. Marie, Toronto, Montreal
2025-04-09
Recruiting
Canadian Cancer Trials Group
Phase 3
196
Calgary, Edmonton, Vancouver, Winnipeg, Hamilton, Ottawa, Toronto, Montreal
2025-04-07
Recruiting
AbbVie
Observational
700
Edmonton, Moncton, St. John's, Greater Sudbury, Kingston
2025-03-28
Recruiting
AstraZeneca
Phase 3
600
Calgary, Edmonton, Winnipeg, Halifax, London, Toronto, Montreal, Québec
2025-03-27
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2/3
150
Calgary, Edmonton, Toronto, Montreal
2025-03-25
Active, closed
Novartis Pharmaceuticals
Phase 3
565
Edmonton, London, Montreal, Québec, Sherbrooke
2025-03-20
Active, closed
Astria Therapeutics, Inc.
Phase 3
157
Ottawa, Edmonton
2025-03-20
Recruiting
Children's Hospital of Eastern Ontario
Observational
625
Edmonton, Ottawa, Toronto, Montreal
2025-03-18
Recruiting
Hoffmann-La Roche
Phase 3
600
Edmonton, Vaughan, Trois-Rivières
2025-03-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Edmonton, Oshawa, Toronto, Chicoutimi, Montreal, Québec, Saskatoon
2025-03-16
Recruiting
NuvOx LLC
Phase 1
18
Edmonton, Montreal
2025-03-13
Active, closed
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
DrugALXN2030
Alexion Pharmaceuticals, Inc.
Phase 2
47
Calgary, Edmonton, Vancouver, London, Toronto
2025-03-07
Recruiting
Tyra Biosciences, Inc
Phase 2
92
Edmonton, Ottawa, Toronto
2025-03-04
Recruiting
AstraZeneca
Phase 3
5,000
Edmonton, Surrey, Vancouver, Winnipeg, Saint John, Halifax, Etobicoke, London
2025-03-03
Recruiting
University of Alberta
Not applicable
30
Edmonton
2025-03-01
Recruiting
AstraZeneca
Phase 3
840
Calgary, Edmonton, Winnipeg, Barrie, Brampton, Hamilton, Toronto, Chicoutimi
2025-03-01
By invitation
Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0
NCT06823115Acute Kidney Injury, Fluid Overload, Prematurity Complications, Risk Factors
Indiana University
Observational
8,000
Vancouver, Toronto, Calgary, Edmonton, Hamilton, Montreal
2025-03-01
Recruiting
Bayer
Phase 1
148
Toronto, Montreal, Sherbrooke, Edmonton
2025-02-28
Recruiting
Incyte Corporation
Phase 3
600
Calgary, Edmonton, Sherwood Park, Vancouver, Winnipeg, Barrie, Cobourg, London
2025-02-28
Recruiting
Summit Therapeutics
Phase 3
780
Edmonton, Etobicoke, London, Montreal
2025-02-27
Recruiting
Bristol-Myers Squibb
Phase 3
530
Edmonton, Chicoutimi, Québec, Rimouski
2025-02-25
Recruiting
University of Alberta
Observational
100
Edmonton, Vancouver, Toronto, Montreal
2025-02-24
Recruiting
Novo Nordisk A/S
Phase 3
510
Calgary, Edmonton, Vancouver, London, Scarborough Village, Toronto, Montreal
2025-02-17
Recruiting
University of Alberta
Not applicable
6,046
Calgary, Edmonton
2025-02-12
Recruiting
LEO Pharma
Phase 3
90
Edmonton, Toronto, Montreal, Québec
2025-02-05
Recruiting
Bristol-Myers Squibb
Phase 1/2
416
Edmonton, Newmarket, Ottawa, Montreal
2025-02-04
Active, closed
NovoCure GmbH
Phase 3
741
Edmonton, Hamilton, Ottawa, Toronto, Montreal, Sherbrooke
2025-02-03
By invitation
Pharvaris Netherlands B.V.
Phase 3
170
Edmonton, Montreal
2025-02-01
Active, closed
Ayaangwaamiziwin Initiative: Carefulness and Preparedness
NCT06893159Point-of-Care Testing, HIV, Syphilis
Unity Health Toronto
Not applicable
10,000
Edmonton, Grande Prairie, Winnipeg, Regina
2025-02-01
Recruiting
Antibiotic Prophylaxis for Neurogenic Bladder Botox
NCT04791579Neurogenic Bladder, Post-operative Urinary Tract Infections
DrugCiprofloxacin
University of Alberta
Phase 2
160
Edmonton
2025-02-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,046
Edmonton, Halifax, Hamilton, Oshawa, Toronto
2025-01-27
Recruiting
Incyte Corporation
Phase 3
180
Calgary, Edmonton, Vancouver, Winnipeg, Halifax, Mississauga, Ottawa, Toronto
2025-01-24
Recruiting
Modifying PEST for Psoriatic Arthritis Screening
NCT06382051Plaque Psoriasis, Psoriatic Arthritis
Novartis Pharmaceuticals
Not applicable
502
Calgary, Edmonton, Kelowna, Surrey, Winnipeg, Fredericton, Barrie, Greater Sudbury
2025-01-23
Active, closed
Preoperative Optimization of Diabetic Patients
NCT06589466Diabetes, Surgery Related Complications Rate
University of Alberta
Observational
46,000
Edmonton
2025-01-22
Recruiting
Incyte Corporation
Phase 3
240
Calgary, Edmonton, Vancouver, Halifax, Hamilton, Toronto, Montreal
2025-01-21
Recruiting
Exercise MRI to Evaluate Cardiorespiratory Fitness in Children With Heart Disease
NCT06325280Pediatric ALL, Congenital Heart Disease, Heart Transplantation
University of Alberta
Observational
20
Edmonton
2025-01-20
Active, closed
Intellia Therapeutics
Phase 3
80
Edmonton, Ottawa
2025-01-15
Recruiting
Immatics US, Inc.
Phase 3
450
Edmonton, Vancouver, Toronto, Montreal
2025-01-14
Recruiting
BlossomHill Therapeutics
Phase 1/2
675
Edmonton, Toronto
2025-01-09
Active, closed
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
Alumis Inc
Phase 3
1,680
Edmonton, Red Deer, Surrey, Ajax, Barrie, Coburg, Guelph, Hamilton
2025-01-08
Recruiting
Pelvic Health Rehabilitation After Breast and Gynecologic Cancer
NCT06822582Gynecologic Cancers, Breast Cancer Female, Incontinence, Incontinence Bowel
Laval University
Not applicable
20
Edmonton, Québec
2025-01-07
Recruiting
IWK Health Centre
Not applicable
787
Edmonton, Vancouver, Fredericton, Moncton, Saint John, Saint Johns, Halifax, Kingston
2025-01-06
Active, closed
Pfizer
Phase 3
1,035
Edmonton, Fredericton, Toronto, Chicoutimi, Montreal
2025-01-06
Recruiting
Fasted Exercise Training in Type 1 Diabetes (FED-T1D)
NCT06748963Diabetes Mellitus, Type 1
University of Alberta
Not applicable
20
Edmonton
2025-01-01
Recruiting
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
NCT06439225Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
DrugsDocetaxel·Carboplatin
Canadian Cancer Trials Group
Phase 3
236
Calgary, Edmonton, Vancouver, Brampton, Kitchener, London, Ottawa, Toronto
2024-12-30
Active, closed
Amgen
Phase 2
61
Edmonton, Brampton, London, Toronto, Montreal
2024-12-26
Recruiting
Cytokinetics
Phase 3
1,800
Edmonton, Kelowna, Surrey, Vancouver, Victoria, Winnipeg, Kingston, London
2024-12-19
Active, closed
Arrowhead Pharmaceuticals
Phase 1
39
Montreal, Edmonton
2024-12-17
Recruiting
Canadian Myeloma Research Group
Phase 2
75
Edmonton, St. John's, Halifax, London, Toronto, Montreal
2024-12-12
Recruiting
Ipsen
Observational
100
Edmonton, Oakville, Toronto
2024-12-05
Active, closed
Biogen
Phase 3
132
Edmonton, Vancouver, Montreal
2024-12-03
Recruiting
Loratadine for the Prevention of G-CSF-related Bone Pain
NCT05421416Stem Cell Transplant Complications
DrugLoratadine
AHS Cancer Control Alberta
Phase 2
78
Edmonton
2024-11-28
Recruiting
ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
NCT06733922Relapsing Remitting Multiple Sclerosis (RRMS)
Novartis Pharmaceuticals
Phase 4
224
Calgary, Edmonton, Burnaby, Vancouver, St. John's, Halifax, Ottawa, Montreal
2024-11-27
Recruiting
International CRDS Registry
NCT06508164Calcium Release Deficiency Syndrome
Population Health Research Institute
Observational
500
Calgary, Edmonton, Vancouver, Hamilton, London, Ottawa, Montreal, Québec
2024-11-21
Active, closed
Pfizer
Phase 3
636
Edmonton, Red Deer, London
2024-11-15
Active, closed
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
DrugTaladegib
Endeavor Biomedicines, Inc.
Phase 2
213
Edmonton, Vancouver, Ajax, Montreal, Sherbrooke, Trois-Rivières
2024-11-15
Recruiting
University of Alberta
Not applicable
100
Calgary, Edmonton, St. Albert, Hamilton, North York, Toronto, Regina
2024-11-14
Recruiting
An Adaptive Design Study of MTX228
NCT06474598Type 1 Diabetes Mellitus
University of Alberta
Phase 2
24
Edmonton
2024-11-14
Recruiting
Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
NCT06637332Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, S. Aureus Bacteremia, S. Aureus Bloodstream Infection
DrugsDaptomycin·Vancomycin
Todd C. Lee MD MPH FIDSA
Phase 4
300
Edmonton, Surrey, St. John's, Hamilton, Toronto, Montreal
2024-11-14
Recruiting
Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
NCT05923970Vaccination Failure, Vaccine Response Impaired
University of Alberta
Observational
200
Edmonton
2024-11-09
Recruiting
Routine vs On-demand ECMO for Lung Transplantation
NCT06615492Respiratory Failure, Interstitial Lung Disease (ILD), Pulmonary Fibrosis, COPD (Chronic Obstructive Pulmonary Disease)
Centre hospitalier de l'Université de Montréal (CHUM)
Not applicable
218
Edmonton, Vancouver, Toronto, Montreal
2024-11-05
Recruiting
High Heated Humidity in Stem Cell Transplant
NCT05358262Autologous Stem Cell Transplant
AHS Cancer Control Alberta
Phase 2
90
Edmonton
2024-11-05
Active, closed
Pharmacist Case Finding and Intervention for Vascular Prevention Trial
NCT06405880Cardiovascular Risk Factors, Blood Pressure, Cardiovascular Disease, Diabetes
University of Alberta
Not applicable
1,003
Edmonton
2024-11-04
Recruiting
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
NCT06217302Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
DrugSotagliflozin
Alessandro Doria
Phase 3
150
Calgary, Edmonton, Vancouver, Toronto, Montreal
2024-10-31
Active, closed
Nutritional Supplementation in Head and Neck Cancers
NCT05379712Malnourishment, Nutritional Deficiency, Undernutrition
AHS Cancer Control Alberta
Phase 2
81
Edmonton
2024-10-25
Recruiting
Pfizer
Phase 3
900
Calgary, Edmonton, Halifax, Oshawa, Chicoutimi, Montreal
2024-10-22
Recruiting
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
NCT06368817Basal Ganglia Germinoma, Diabetes Insipidus, Germinoma, Pineal Region Germinoma
DrugsParaplatin·Etoposide·Carboplatin
Children's Oncology Group
Phase 2
240
Edmonton, Vancouver, Winnipeg, Halifax, Hamilton, London, Toronto, Montreal
2024-10-22
Active, closed
Amgen
Phase 3
19
Calgary, Edmonton, Vancouver, Montreal
2024-10-22
Active, closed
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
NCT06553768Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
DrugMaralixibat
Mirum Pharmaceuticals, Inc.
Phase 3
90
Edmonton
2024-10-14
Recruiting
Australasian Gastro-Intestinal Trials Group
Phase 2
78
Edmonton, Vancouver, London, Ottawa, Toronto, Regina, Saskatoon
2024-10-14
Recruiting
Alnylam Pharmaceuticals
Phase 1
66
Edmonton, Montreal, Ottawa, Vancouver
2024-10-14
Recruiting
Boehringer Ingelheim
Phase 2
588
Edmonton, Vancouver, Toronto, Montreal
2024-10-11
Active, closed
Incyte Corporation
Phase 3
349
Calgary, Edmonton, Sherwood Park, Barrie, Cobourg, London, Toronto, Québec
2024-10-10
Active, closed
Incyte Corporation
Phase 3
346
Edmonton, Barrie, London, Toronto, Québec, Saskatoon
2024-10-10
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
2,150
Edmonton, Toronto, Vaughan, Montreal, Terrebonne
2024-10-04
Recruiting
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
NCT05947955Acute Respiratory Distress Syndrome, Infections
BioAegis Therapeutics Inc.
Phase 2
600
Calgary, Edmonton, North Vancouver, Toronto, Montreal
2024-10-03
Recruiting
NoNO Inc.
Phase 2
600
Calgary, Edmonton, Vancouver, Winnipeg, Hamilton, Ottawa, Toronto, Saskatoon
2024-10-02
Recruiting
McGill University Health Centre/Research Institute of the McGill University Health Centre
Not applicable
548
Edmonton, Abbotsford British Columbia, Mission, Dorchester, Smiths Crossing, Truro, Kingston, Kitchener
2024-10-01
Recruiting
ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
NCT06320431Acute Ischemic Stroke AIS, Stroke Acute, Stroke, Acute, Stroke Ischemic
DrugTenecteplase
University of Calgary
Phase 3
4,000
Calgary, Medicine Hat, Red Deer, Edmonton, Kelowna, New Westminster, Vancouver, Brandon
2024-09-26
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Edmonton, Kelowna, Vancouver, Moncton, Halifax, Hamilton, Windsor, Montreal
2024-09-26
Active, closed
A Multi-Centre Study in Patients Undergoing Total Hip Arthroplasty With the Smith+Nephew CATALYSTEM™ Primary Hip System
NCT06564636Total Hip Arthroplasty (THA), Osteoarthritis, Degenerative Joint Disease, Inflammatory Arthritis
Smith & Nephew, Inc.
Observational
119
Edmonton, Vancouver, Winnipeg, London
2024-09-26
Recruiting
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
NCT05554406Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
DrugsVyxeos·Azacytidine·Ara-C·Daunorubicin
National Cancer Institute (NCI)
Phase 2
335
Calgary, Edmonton, Winnipeg, Halifax, Ottawa, Toronto, Greenfield Park, Montreal
2024-09-25
Recruiting
Janssen Research & Development, LLC
Phase 2/3
274
Edmonton
2024-09-19
Active, closed
Hoffmann-La Roche
Phase 3
400
Edmonton
2024-09-17
Active, closed
Novo Nordisk A/S
Phase 4
500
Calgary, Edmonton, Vancouver, Markham, Toronto, West Hamilton, Montreal
2024-09-17
Recruiting
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06081348Neurodevelopmental Disorders, Autism, Autism Spectrum Disorder, Fragile X Syndrome
DrugsZoloft·Sertraline
Holland Bloorview Kids Rehabilitation Hospital
Phase 2
130
Calgary, Edmonton, Halifax, Hamilton, Kingston, London, Toronto
2024-09-16
Recruiting
National Cancer Institute (NCI)
Phase 2
153
Calgary, Edmonton, Winnipeg, Halifax, Hamilton, Toronto, Greenfield Park, Montreal
2024-09-13
Recruiting
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
DrugsDoxorubicin·Keytruda·Pembrolizumab
National Cancer Institute (NCI)
Phase 3
365
Calgary, Edmonton, Vancouver, Winnipeg, Hamilton, Ottawa, Toronto, Québec
2024-09-11
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
130
Edmonton, Hamilton, Montreal
2024-09-11
Recruiting
Regeneron Pharmaceuticals
Phase 3
560
Calgary, Edmonton, London, Toronto, Montreal, Québec
2024-09-09
Recruiting
AbbVie
Phase 2
590
Calgary, Edmonton, Greater Sudbury, London, Vaughan, Montreal, Québec
2024-09-04
Active, closed
Takeda
Phase 3
2,099
Calgary, Edmonton, Red Deer, Surrey, Winnipeg, St. John's, Ajax, Barrie
2024-09-04
Recruiting
University of Alberta
Not applicable
180
Calgary, Edmonton
2024-09-01
Active, closed
Boehringer Ingelheim
Phase 3
8,371
Edmonton, Kamloops, Kelowna, Prince George, Surrey, Vancouver, Québec, Halifax
2024-08-30
Recruiting
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
NCT06351592Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Regeneron Pharmaceuticals
Phase 1/2
54
Edmonton, London, Toronto, Montreal
2024-08-28
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin
AstraZeneca
Phase 2
257
Edmonton, Montreal
2024-08-22
Recruiting
Colorado Prevention Center
Phase 3
2,600
Calgary, Edmonton, North Vancouver, Surrey, Victoria, Winnipeg, Greater Sudbury, Kingston
2024-08-20
Recruiting
Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)
NCT05663775Immune-related Adverse Event, Diarrhea, Advanced Melanoma, Advanced Rectal Carcinoma
DrugMesalamine
AHS Cancer Control Alberta
Phase 2
20
Edmonton
2024-08-20
Active, closed
AbbVie
Phase 3
699
Calgary, Edmonton, Vancouver, Halifax, Hamilton, Markham, Niagara Falls, Toronto
2024-08-19
Recruiting
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT06371417Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
DrugRAY121
Chugai Pharmaceutical
Phase 1
144
Edmonton, Montreal, Rimouski, Sherbrooke
2024-08-19
Recruiting
AstraZeneca
Phase 3
620
Edmonton, Halifax, Brampton, Toronto, Montreal
2024-08-12
Recruiting
University of Calgary
Not applicable
354
Calgary, Edmonton
2024-08-10
Recruiting
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
NCT06257706Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
DrugVedolizumab
Alimentiv Inc.
Phase 4
304
Calgary, Edmonton, Bridgewater, London, Toronto
2024-08-07
Recruiting
Prehab Prior to Stem Cell Transplantation in Multiple Myeloma
NCT06280924Multiple Myeloma, Exercise, Prehabilitation
University of Alberta
Not applicable
30
Edmonton
2024-08-06
Recruiting
Inspiratory Muscle Training in Lung Transplant Candidates
NCT06370832Inspiratory Muscle Training
University Health Network, Toronto
Not applicable
90
Edmonton, Vancouver, Toronto, Montreal
2024-08-06
Active, closed
GlaxoSmithKline
Phase 3
10,212
Edmonton, New Westminster, Surrey, Vancouver, Victoria, Halifax, Truro, Greater Sudbury
2024-08-01
Recruiting
Basking Biosciences, Inc.
Phase 2
228
Calgary, Edmonton, Vancouver, Ottawa
2024-07-31
Active, closed
Annexon, Inc.
Phase 3
659
Calgary, Edmonton, London, Ottawa
2024-07-30
Active, closed
OncoVerity, Inc.
Phase 2
140
Calgary, Edmonton, Vancouver, London, Ottawa, Toronto, Saskatoon
2024-07-22
Active, closed
Celldex Therapeutics
Phase 3
976
Edmonton, Hamilton, London, North Bay, Ottawa, Richmond Hill, Toronto, Windsor
2024-07-19
Recruiting
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
NCT06521554Locally Advanced Solid Tumor, Metastatic Solid Tumor
Nuvalent Inc.
Phase 1
200
Edmonton, Toronto
2024-07-18
Active, closed
Celldex Therapeutics
Phase 3
963
Edmonton, St. John's, Hamilton, Markham, Richmond Hill, Toronto, Calgary
2024-07-11
Recruiting
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
NCT06208657Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor, Recurrent Cancer
DrugsPaxalisib·Opdualag·Temozolomide·Irinotecan
Australian & New Zealand Children's Haematology/Oncology Group
Phase 1/2
90
Edmonton, Montreal, Ottawa, Toronto, Vancouver
2024-07-10
Recruiting
Colorado Prevention Center
Phase 3
1,500
Edmonton, Surrey, Greater Sudbury, London, North York, Toronto, Montreal, Sherbrooke
2024-07-09
Recruiting
Breast cancEr, FITness and ExeRcise for Heart Health: The BE-FITTER Study
NCT06595147Breast Cancer, Disability Physical, Heart Failure, Cardiotoxicity
University of Alberta
Not applicable
60
Edmonton
2024-07-01
Active, closed
AbbVie
Phase 3
1,400
Calgary, Edmonton, Kelowna, Fredericton, St. John's, Cobourg, Hamilton, London
2024-06-27
Recruiting
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
NCT06064097Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8
DrugsCis-platinum·CDDP·Platinol-AQ·Opdivo
National Cancer Institute (NCI)
Phase 2
50
Calgary, Edmonton, Toronto, Montreal, Sherbrooke
2024-06-25
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Calgary, Edmonton, Kelowna, Vancouver, Winnipeg, Saint John, Halifax, Barrie
2024-06-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Calgary, Edmonton, Vancouver, Winnipeg, Moncton, Halifax, Hamilton, Kingston
2024-06-24
By invitation
Sarepta Therapeutics, Inc.
Phase 1/2
60
Calgary, Edmonton, Montreal
2024-06-19
Active, closed
Ocugen
Phase 3
140
Calgary, Edmonton, Vancouver, Toronto, Montreal
2024-06-18
Recruiting
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
NCT05564390Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
DrugsEmavusertib·Olutasidenib·Vyxeos·Mylotarg
National Cancer Institute (NCI)
Phase 2
2,000
Calgary, Edmonton, Winnipeg, Halifax, Hamilton, Ottawa, Toronto, Greenfield Park
2024-06-18
Recruiting
AHS Cancer Control Alberta
Phase 2
24
Edmonton
2024-06-18
Active, closed
BioMarin Pharmaceutical
Phase 3
80
Edmonton, Toronto, Montreal
2024-06-17
Recruiting
University of Alberta
Phase 2/3
30
Edmonton
2024-06-15
Active, closed
AbbVie
Phase 3
184
Calgary, Edmonton, Richmond Hill, Québec
2024-06-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
550
Edmonton, Kitchener, Toronto, Montreal
2024-06-11
Recruiting
LEO Pharma
Phase 3
195
Burlington, Calgary, Edmonton, Hamilton, Niagara Falls, Saskatoon, Windsor, Winnipeg
2024-06-10
Active, closed
Janssen Research & Development, LLC
Phase 1
108
Edmonton, Toronto
2024-06-07
Recruiting
X4 Pharmaceuticals
Phase 3
176
Edmonton, Vancouver
2024-06-06
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Calgary, Edmonton, Lethbridge, New Westminster, Vancouver, Kentville, Barrie, London
2024-06-05
Recruiting
Immunocore Ltd
Phase 3
680
Toronto, Edmonton
2024-06-05
Recruiting
University of British Columbia
Observational
4,400
Edmonton, Kelowna, Prince George, Surrey, Brandon, Winnipeg, Saint John, St. John's
2024-06-03
Recruiting
Alberta Chiropractic SelfBack Study
NCT06347991Chronic Low-back Pain
University of Alberta
Not applicable
100
Edmonton
2024-05-24
Recruiting
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
NCT06343402Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C
DrugsBBO-10203·Pembrolizumab
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
350
Edmonton, Hamilton, Toronto, Montreal
2024-05-22
Recruiting
Daiichi Sankyo
Phase 3
540
Brampton, Edmonton, Québec, Toronto, Winnipeg
2024-05-21
Active, closed
Syndax Pharmaceuticals
Phase 1
96
Edmonton, Vancouver, Montreal
2024-05-21
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Calgary, Edmonton, Red Deer, Vancouver, Moncton, St. John's, Hamilton, London
2024-05-20
Recruiting
Nimodipine Variability in SAH
NCT07065903Subarachnoid Aneurysm Hemorrhage, Subarachnoid Hemorrhage, Aneurysmal
University of Alberta
Observational
500
Edmonton, Toronto
2024-05-13
Active, closed
Sanofi
Phase 3
1,541
Calgary, Edmonton, Red Deer, Kelowna, Surrey, Winnipeg, Ajax, London
2024-05-08
Recruiting
PSC Partners Seeking a Cure
Observational
2,000
Edmonton, Toronto, Montreal
2024-05-06
Active, closed
Eli Lilly and Company
Phase 3
10,000
Calgary, Chicoutimi, Courtice, Edmonton, London, Moncton, North York, Oshawa
2024-04-30
Active, closed
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948Atopic Dermatitis
DrugAPG777
Apogee Therapeutics, Inc.
Phase 2
470
Calgary, Edmonton, Vancouver, Winnipeg, Fredericton, Ajax, Markham, Mississauga
2024-04-29
Recruiting
AstraZeneca
Phase 3
582
Edmonton, Montreal
2024-04-29
Recruiting
CSL Behring
Phase 2/3
3,110
Edmonton, Halifax, Hamilton, Kingston, London, Oshawa, Montreal, Longueuil
2024-04-27
Recruiting
A Platform Trial for Gram Negative Bloodstream Infections
NCT06537609Gram-negative Bacteremia
Sunnybrook Health Sciences Centre
Not applicable
2,500
Calgary, Edmonton, Surrey, Vancouver, Winnipeg, Fredericton, St. John's, Mississauga
2024-04-24
Recruiting
Ottawa Hospital Research Institute
Not applicable
200
Edmonton, Winnipeg, Kingston, Ottawa, Toronto, Lévis, Montreal, Québec
2024-04-22
Recruiting
Prediction of Intraventricular Hemorrhage Using Echocardiography and Near Infrared Spectroscopy
NCT05708105Intraventricular Hemorrhage of Newborn Grade 2, Intraventricular Hemorrhage of Newborn Grade 3, Intraventricular Haemorrhage Grade IV
Mount Sinai Hospital, Canada
Observational
380
Calgary, Edmonton, London, Toronto
2024-04-22
Recruiting
National Cancer Institute (NCI)
Phase 3
478
Calgary, Edmonton, Vancouver, Winnipeg, St. John's, Halifax, Hamilton, London
2024-04-19
Active, closed
Takeda
Phase 4
50
Edmonton, London, North Bay, North York, Oakville, Vaughan, Montreal
2024-04-18
Active, closed
Bristol-Myers Squibb
Phase 3
44
Edmonton, Toronto
2024-04-17
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Edmonton, Burnaby, Vancouver, Halifax, Hamilton, Ottawa, Toronto, Gatineau
2024-04-16
Active, closed
Celldex Therapeutics
Phase 2
140
Edmonton, Barrie, Etobicoke, Guelph, London, Toronto
2024-04-12
Recruiting
Canadian Cancer Trials Group
Phase 3
570
Edmonton, Kelowna, Vancouver, Winnipeg, Moncton, Saint John, St. John's, Barrie
2024-04-10
Recruiting
Sanofi Pasteur, a Sanofi Company
Phase 1/2
800
Edmonton, Barrie, Toronto, Montreal, Québec, Sherbrooke
2024-04-05
Recruiting
PSMA-Guided Ablation of the Prostate
NCT06003556Prostate Cancer, Localized Prostate Carcinoma
University of Alberta
Phase 2
138
Calgary, Edmonton, Toronto
2024-04-02
Active, closed
AstraZeneca
Phase 3
2,554
Edmonton, Vancouver, Winnipeg, Halifax, Sydney, Brampton, Concord, London
2024-03-29
Recruiting
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
NCT05828069Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
DrugTovorafenib
National Cancer Institute (NCI)
Phase 2
48
Edmonton, Vancouver, Halifax, Hamilton, London, Toronto, Montreal, Sherbrooke
2024-03-28
Recruiting
University of Alberta
Not applicable
148
Edmonton, Toronto
2024-03-25
Active, closed
AbbVie
Phase 2
156
Edmonton, Vaughan
2024-03-23
Active, closed
Alimentiv Inc.
Observational
300
Edmonton, Vancouver, Brampton, London, Mississauga, Oakville, Ottawa, Scarborough Village
2024-03-20
Recruiting
Impact of Metabolic Health Patterns And Breast Cancer Over Time in Women
NCT05432856Cardiovascular Diseases, Cardiovascular Morbidity, Metabolic Disease
University of Alberta
Not applicable
65
Edmonton, Toronto
2024-03-13
Recruiting
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT06217822Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression
Bayer
Phase 1
198
Edmonton, Vancouver, Hamilton, Toronto, Montreal, Sherbrooke
2024-03-07
By invitation
Sarepta Therapeutics, Inc.
Phase 1/2
78
Calgary, Edmonton, Montreal
2024-03-04
Recruiting
The STOP-MED CTRCD Trial
NCT06183437Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity
Dinesh Thavendiranathan
Phase 4
335
Edmonton, Winnipeg, Hamilton, Ottawa, Toronto
2024-03-04
Active, closed
Sanofi
Phase 3
464
Calgary, Edmonton, Burlington, Hamilton, London, Toronto, Québec, Regina
2024-02-29
Recruiting
Continence, Sexual Function, Fitness and the Health of Men After Surgery for Prostate Cancer
NCT06072911Prostate Cancer, Incontinence, Metabolic Disease
University of Alberta
Not applicable
106
Edmonton
2024-02-27
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
Edmonton, Toronto, Vancouver
2024-02-26
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Calgary, Edmonton, Brampton, Etobicoke, Ottawa, Toronto, Greenfield Park, Montreal
2024-02-21
Active, closed
Eli Lilly and Company
Phase 3
1,250
Calgary, Edmonton, Brampton, Hamilton, Sarnia, Toronto, Whitby, Montreal
2024-02-21
Active, closed
AbbVie
Observational
1,200
Calgary, Edmonton, New Westminster, Winnipeg, Halifax, Barrie, London, Mississauga
2024-02-19
Recruiting
St. Justine's Hospital
Observational
3,000
Calgary, Edmonton, Vancouver, Halifax, Hamilton, Kingston, London, Oshawa
2024-02-13
Recruiting
Nerve Transfer to Improve Function in High Level Tetraplegia
NCT06288763Cervical Spinal Cord Injury, Tetraplegia
Washington University School of Medicine
Observational
30
Edmonton
2024-02-05
Recruiting
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma
DrugsRelatlimab·Opdivo·Nivolumab
National Cancer Institute (NCI)
Phase 2/3
992
Calgary, Edmonton, Vancouver, Kitchener, London, Ottawa, Toronto, Regina
2024-02-02
Active, closed
Astellas Gene Therapies
Not applicable
119
Edmonton, Montreal
2024-02-01
Active, closed
Incyte Corporation
Phase 3
617
Calgary, Edmonton, Surrey, Winnipeg, Fredericton, Barrie, Hamilton, London
2024-01-30
Recruiting
Hemianopsia Rehabilitation After Stroke or Brain Injury
NCT06241209Hemianopsia, Visual Field Defect, Peripheral, Visual Impairment
University of Alberta
Not applicable
40
Edmonton
2024-01-25
Recruiting
Colorado Prevention Center
Phase 3
5,200
Calgary, Edmonton, Kamloops, North Vancouver, Surrey, Vancouver, Winnipeg, Cambridge
2024-01-17
Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsErbitux·Cetuximab
AVEO Pharmaceuticals, Inc.
Phase 3
410
Calgary, Edmonton, Ottawa, Toronto, Montreal
2024-01-11
Recruiting
Ottawa Heart Institute Research Corporation
Not applicable
576
Calgary, Edmonton, Ottawa, Toronto, Montreal
2024-01-08
Recruiting
University of Alberta
Phase 2
528
Edmonton
2024-01-05
Recruiting
University of Alberta
Phase 1
30
Edmonton
2024-01-05
By invitation
Sanofi
Phase 3
90
Edmonton, Vancouver, Burlington, Hamilton, Montreal, Sherbrooke
2024-01-03
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
124
Calgary, Edmonton, Winnepeg, Oakville, Trois-Rivières
2024-01-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Edmonton, Ottawa, Toronto, Greenfield Park, Montreal, Québec, Sherbrooke
2023-12-31
Active, closed
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
NCT06046222Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
NS Pharma, Inc.
Phase 2
45
Edmonton, Hamilton, Toronto
2023-12-20
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Calgary, Edmonton, Halifax, London
2023-12-20
Recruiting
Cord Clamping Among Neonates With Congenital Heart Disease
NCT06153459Congenital Heart Disease (CHD)
Carl Backes, MD
Not applicable
500
Edmonton, Halifax, Toronto
2023-12-19
Recruiting
McGill University Health Centre/Research Institute of the McGill University Health Centre
Observational
30
Edmonton, Montreal
2023-12-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Edmonton, Abbotsford British Columbia, Mississauga, Ottawa, Toronto, Montreal, Québec
2023-12-18
Recruiting
AstraZeneca
Phase 3
1,145
Calgary, Edmonton, Kelowna, Kingston, London, Toronto, Chicoutimi, Montreal
2023-12-14
Active, closed
Sanofi
Phase 3
1,655
Edmonton, St. John's, London, Ottawa, Gatineau, Granby, Lévis, Québec
2023-12-13
Active, closed
AstraZeneca
Phase 2
108
Edmonton, Vancouver, Halifax, Barrie, Toronto, Montreal
2023-12-13
Active, closed
Hoffmann-La Roche
Phase 3
1,050
Edmonton, Barrie, Mississauga, Oshawa, Thunder Bay, Toronto, Chicoutimi, Lévis
2023-12-11
Recruiting
AbbVie
Phase 3
110
Calgary, Edmonton, Vancouver, London
2023-12-11
Recruiting
Eikon Therapeutics
Phase 1/2
156
Edmonton, Toronto
2023-12-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Calgary, Edmonton, Vancouver, Mississauga, Chicoutimi, Montreal
2023-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Edmonton, Brampton, Toronto, Montreal
2023-12-06
Recruiting
Akero Therapeutics, Inc
Phase 3
1,650
Edmonton, Hamilton, Toronto, Vaughan, Montreal, Terrebonne
2023-12-01
Recruiting
BioMarin Pharmaceutical
Observational
400
Edmonton, Toronto, Montreal
2023-11-27
Active, closed
University of Alberta
Phase 1
8
Edmonton
2023-11-27
Active, closed
Nektar Therapeutics
Phase 2
396
Calgary, Edmonton, Kelowna, Surrey, Barrie, Markham, Peterborough, Richmond Hill
2023-11-15
Active, closed
AbbVie
Phase 3
289
Calgary, Edmonton, Halifax, Vaughan, Montreal
2023-11-15
Active, closed
Novartis Pharmaceuticals
Phase 3
470
Edmonton, Hamilton, London, Niagara Falls, Québec, Verdun
2023-11-15
Active, closed
GlaxoSmithKline
Phase 2
316
Calgary, Edmonton, Toronto, Montreal
2023-11-14
Active, closed
BeOne Medicines
Phase 3
652
Calgary, Edmonton, Winnipeg, Oshawa, Toronto, Greenfield Park, Montreal, SaintJerome
2023-11-11
Active, closed
Akero Therapeutics, Inc
Phase 3
700
Edmonton, Hamilton, Toronto, Vaughan, Terrebonne
2023-11-10
Active, closed
Kite, A Gilead Company
Phase 1
21
Edmonton, Halifax, Montreal
2023-11-09
Active, closed
AstraZeneca
Phase 3
863
Edmonton, Ottawa, Toronto, Montreal, Québec
2023-11-09
Active, closed
Pfizer
Phase 3
1,571
Calgary, Edmonton, Vancouver, Winnipeg, Barrie, Greater Sudbury, London, Mississauga
2023-11-08
Active, closed
AbbVie
Phase 3
122
Edmonton, Vancouver, Halifax, Toronto
2023-11-06
Recruiting
Tanja Andrea Gruber
Phase 1/2
90
Calgary, Edmonton, Vancouver, Hamilton, Montreal, Québec
2023-11-03
Recruiting
Trifecta-Lung cfDNA-MMDx Study
NCT05837663Lung Transplantation
University of Alberta
Observational
600
Edmonton, Toronto
2023-11-01
Recruiting
University of Alberta
Phase 4
30
Edmonton
2023-10-31
Active, closed
IDEAYA Biosciences
Phase 2/3
420
Edmonton, Vancouver, Toronto, Montreal
2023-10-31
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Calgary, Edmonton, Lethbridge, New Westminster, Vancouver, Kentville, Barrie, London
2023-10-25
Recruiting
University of Calgary
Phase 4
210
Calgary, Edmonton, Vancouver, Halifax, Brampton, Brantford, Hamilton, London
2023-10-25
Active, closed
GlaxoSmithKline
Phase 1/2
42
Edmonton, Toronto, Montreal
2023-10-24
Active, closed
AstraZeneca
Phase 3
895
Calgary, Edmonton, Winnipeg, Halifax, Barrie, Oshawa, Toronto, Lévis
2023-10-24
Active, closed
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 2
114
Edmonton, North Vancouver, Halifax, Toronto
2023-10-23
Active, closed
Celgene
Phase 3
79
Edmonton, Hamilton, Montreal
2023-10-16
Active, closed
Eli Lilly and Company
Phase 3
160
Edmonton, Hamilton, Toronto, Chicoutimi
2023-10-16
Active, closed
Janssen Research & Development, LLC
Phase 3
311
Edmonton, Markham, Peterborough, Richmond Hill, Montreal, Québec, Saskatoon
2023-10-12
Active, closed
Janssen Research & Development, LLC
Phase 3
684
Calgary, Edmonton, Surrey, London, Newmarket, Toronto, Windsor, Montreal
2023-10-12
Recruiting
AbbVie
Phase 3
1,500
Calgary, Edmonton, Surrey, Winnipeg, Barrie, Greater Sudbury, Hamilton, Markham
2023-10-11
Active, closed
Stichting European Myeloma Network
Phase 3
759
Edmonton, Hamilton, Montreal, Ottawa, Québec, Toronto, Vancouver
2023-10-10
Recruiting
Sanofi
Phase 3
180
Edmonton, Vancouver, Toronto
2023-10-10
Active, closed
AstraZeneca
Phase 3
5,511
Calgary, Edmonton, Kelowna, North Vancouver, Barrie, Greater Sudbury, Kingston, Thunder Bay
2023-10-05
Recruiting
DalCor Pharmaceuticals
Phase 3
2,000
Calgary, Edmonton, Abbotsford British Columbia, Burnaby, Kamloops, North Vancouver, Vancouver, Victoria
2023-10-03
Recruiting
Pfizer
Phase 4
80
Calgary, Edmonton, Montreal
2023-10-03
Recruiting
University of Alberta
Not applicable
240
Edmonton
2023-10-01
Active, closed
University of Alberta
Not applicable
103
Edmonton
2023-10-01
Recruiting
AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05916339ADHD, Autism Spectrum Disorder
Daniel Coury
Phase 4
500
Edmonton, Toronto
2023-10-01
Active, closed
Astria Therapeutics, Inc.
Phase 2
56
Edmonton, Ottawa
2023-09-26
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
412
Calgary, Edmonton, Oshawa, Toronto
2023-09-22
By invitation
Denali Therapeutics Inc.
Phase 2/3
99
Edmonton, Toronto, Montreal
2023-09-20
Recruiting
University of Alberta
Not applicable
30
Edmonton
2023-09-20
Active, closed
Metabolic and Inflammatory Outcomes of the Ketogenic Diet Comparing Saturated and Unsaturated Fat Sources
NCT05681468PreDiabetes, Diabetes Mellitus, Type 2, Overweight and Obesity
University of Alberta
Not applicable
164
Edmonton
2023-09-18
Recruiting
Left vs Left Randomized Clinical Trial
NCT05650658Heart Failure, Heart Failure With Reduced Ejection Fraction, AV Block, LBBB
Baylor College of Medicine
Not applicable
2,136
Edmonton, Vancouver, Victoria, Halifax, Hamilton, Newmarket, Ottawa, Toronto
2023-09-13
Recruiting
Gilead Sciences
Phase 3
402
Calgary, Edmonton, Montreal, Ottawa, Québec, Toronto, Vancouver
2023-09-07
Active, closed
Cytokinetics
Phase 3
500
Edmonton, Winnipeg, Greater Sudbury, Montreal, Halifax
2023-08-31
Recruiting
Ipsen
Phase 3
276
Edmonton, Toronto
2023-08-31
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 3
2,769
Edmonton, Ajax, Etobicoke, Hamilton, Winchester, Windsor
2023-08-30
Recruiting
Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial
NCT05955924Non-melanoma Skin Cancer, Carcinoma, Squamous Cell, Carcinoma, Basal Cell, Keratinocyte Carcinoma
DrugNicotinamide
Women's College Hospital
Phase 3
396
Calgary, Edmonton, Vancouver, Ottawa, Toronto
2023-08-28
Recruiting
AstraZeneca
Phase 3
231
Edmonton, Burlington, Hamilton, Windsor, Montreal
2023-08-24
Active, closed
Erasca, Inc.
Phase 1
86
Edmonton, Vancouver, London, Toronto
2023-08-17
Recruiting
Epineuron Technologies Inc.
Not applicable
110
Edmonton, Saint John, Hamilton, London, Newmarket, Toronto
2023-08-11
Recruiting
Personalized B-fructan Diet in Inflammatory Bowel Disease Patients
NCT05615779Inflammatory Bowel Diseases, Ulcerative Colitis
University of Manitoba
Not applicable
600
Edmonton, Winnipeg
2023-08-01
Recruiting
GlaxoSmithKline
Phase 3
892
Edmonton, Halifax, Ottawa, Toronto, Montreal
2023-08-01
Active, closed
AbbVie
Phase 3
1,014
Calgary, Edmonton, Winnipeg, Toronto, Sherbrooke
2023-07-25
Recruiting
University of Alberta
Phase 3
2,800
Edmonton
2023-07-25
Recruiting
Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)
NCT05114096Preterm Birth, Premature Birth, Complication of Prematurity, Obstetric Labor, Premature
McMaster University
Phase 4
3,254
Calgary, Edmonton, New Westminster, Surrey, Vancouver, Victoria, Winnipeg, Fredericton
2023-07-20
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,089
Edmonton, Vancouver, Brampton, Toronto, Montreal, Québec
2023-07-19
Recruiting
Kartos Therapeutics, Inc.
Phase 2/3
268
Edmonton, Montreal
2023-07-17
Rows per page Showing 1–500 of 1018
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Canadian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 November 2026. https://priyalifescience.com/clinical-trials-canada/city/edmonton

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Canada and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,553 studies in total at the last sync on 10 Nov 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,018 of those studies with a site in Edmonton.

How many clinical trials are recruiting in Edmonton?

527 of the 1,018 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:20 UTC sync. A further 42 have not yet opened recruitment, 425 are active but closed to new participants, and 24 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Edmonton), 1,018 studies
PhaseStudiesRecruitingShare
Phase 341217340.5%
Not applicable16510216.2%
Phase 21597915.6%
Observational1228212%
Phase 1/249314.8%
Phase 2/341204%
Phase 139193.8%
Phase 428192.8%
Early Phase 1320.3%

Most active sponsors

Lead sponsors with the most studies (Edmonton)
Lead sponsorStudiesRecruiting
University of Alberta175119
AstraZeneca5223
AbbVie3610
National Cancer Institute (NCI)2711
Merck Sharp & Dohme LLC2613
Janssen Research & Development, LLC227
AHS Cancer Control Alberta2112
Canadian Cancer Trials Group2112
Pfizer2110
Novartis Pharmaceuticals209
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.